These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27673352)

  • 1. Impact of the Omnipod
    Polonsky WH; Hessler D; Layne JE; Zisser H
    Diabetes Technol Ther; 2016 Oct; 18(10):664-670. PubMed ID: 27673352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of OMNIPOD® on the quality of life of adolescents with type 1 diabetes.
    Nivet E; Lo G; Nivot-Adamiak S; Guitteny MA; De Kerdanet M
    Arch Pediatr; 2022 Jan; 29(1):21-26. PubMed ID: 34753634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.
    Kong YW; Yuan CY; Kiburg K; Brown K; Trawley S; Partovi A; Roem K; Pham C; Harrison N; Fourlanos S; Ekinci EI; O'Neal DN
    J Clin Endocrinol Metab; 2024 Jul; 109(8):1984-1995. PubMed ID: 38373265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management.
    Adams RN; Tanenbaum ML; Hanes SJ; Ambrosino JM; Ly TT; Maahs DM; Naranjo D; Walders-Abramson N; Weinzimer SA; Buckingham BA; Hood KK
    Diabetes Technol Ther; 2018 Oct; 20(10):648-653. PubMed ID: 30239219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion.
    Layne JE; Parkin CG; Zisser H
    J Diabetes Sci Technol; 2016 Sep; 10(5):1130-5. PubMed ID: 27290737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes.
    Polonsky WH; Fisher L; Hessler D; Edelman SV
    Diabetes Technol Ther; 2015 Nov; 17(11):773-9. PubMed ID: 26167948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users.
    Polonsky WH; Hessler D
    Diabetes Technol Ther; 2013 Apr; 15(4):295-301. PubMed ID: 23427866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes.
    Lebenthal Y; Lazar L; Benzaquen H; Shalitin S; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):411-7. PubMed ID: 22283640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and diabetes knowledge of young persons with type 1 diabetes: Influence of treatment modalities and demographics.
    O'Neil KJ; Jonnalagadda SS; Hopkins BL; Kicklighter JR
    J Am Diet Assoc; 2005 Jan; 105(1):85-91. PubMed ID: 15635351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Insulin Pump Devices in Real Life: The AWeSoMe Study Group Prospective Experience.
    Rachmiel M; Levy-Shraga Y; Gruber N; Pinhas-Hamiel O; Barash G; Pivko-Levy D; Landau Z
    Diabetes Technol Ther; 2019 Mar; 21(3):138-145. PubMed ID: 30702335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WHICH FACTORS MAY AFFECT THE QUALITY OF LIFE IN PATIENTS WITH TYPE 1 DIABETES MELLITUS USING THE MEDTRONIC VEO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP?
    Thomakos P; Panagopoulos G; Kepaptsoglou O; Zoupas C; Mitrakou A
    Georgian Med News; 2018 Apr; (277):61-67. PubMed ID: 29745917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type.
    Franceschi R; Pertile R; Marigliano M; Mozzillo E; Maffeis C; Morotti E; Di Candia F; Fedi L; Iafusco D; Zanfardino A; Cauvin V; Maltoni G; Zucchini S; Cherubini V; Tiberi V; Minuto N; Bassi M; Rabbone I; Savastio S; Tinti D; Tornese G; Schiaffini R; Passanisi S; Lombardo F; Bonfanti R; Scaramuzza A; Troncone A
    Diabet Med; 2024 Jun; 41(6):e15307. PubMed ID: 38383984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale.
    Sakane N; Murata T; Tone A; Kato K; Kimura M; Kawashima S; Sawaki H; Hirota Y; Okada A; Kuroda A; Matsuhisa M; Watanabe T; Suganuma A; Nirengi S; Toyoda M
    Diabetes Technol Ther; 2020 Mar; 22(3):216-221. PubMed ID: 31638420
    [No Abstract]   [Full Text] [Related]  

  • 14. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System.
    Polonsky WH; Hood KK; Levy CJ; MacLeish SA; Hirsch IB; Brown SA; Bode BW; Carlson AL; Shah VN; Weinstock RS; Bhargava A; Jones TC; Aleppo G; Mehta SN; Laffel LM; Forlenza GP; Sherr JL; Huyett LM; Vienneau TE; Ly TT;
    Diabetes Res Clin Pract; 2022 Aug; 190():109998. PubMed ID: 35853530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of quality of life in adults with type 1 diabetes treated with continuous subcutaneous insulin injection.
    Franciosi M; Maione A; Pomili B; Amoretti R; Busetto E; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Ponzi P; Vitacolonna E; Nicolucci A
    Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):7-14. PubMed ID: 19747804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.
    Polonsky WH; Hessler D; Ruedy KJ; Beck RW;
    Diabetes Care; 2017 Jun; 40(6):736-741. PubMed ID: 28389582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Real-World Outcomes of Omnipod Initiation in People with Type 1 Diabetes (COPPER study): Evidence from the LMC Diabetes Registry.
    Brown RE; Vienneau T; Aronson R
    Diabet Med; 2021 Jun; 38(6):e14420. PubMed ID: 33040383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes.
    Marks BE; Meighan S; Zehra A; Douvas JL; Rearson A; Suresh R; Brown EA; Wolf RM
    Diabetes Technol Ther; 2023 Nov; 25(11):782-789. PubMed ID: 37646634
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus.
    Rubin RR; Peyrot M; Chen X; Frias JP
    Diabetes Technol Ther; 2010 Nov; 12(11):901-6. PubMed ID: 20879963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes.
    Forlenza GP; Buckingham BA; Christiansen MP; Wadwa RP; Peyser TA; Lee JB; O'Connor J; Dassau E; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2019 May; 21(5):265-272. PubMed ID: 30925077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.